Class of antiretroviral drugs and the risk of myocardial infarction.

By N. Friis‐Møller, P. Reiss, C. Sabin, R. Weber, A. Monforte, W. El-Sadr, R. Thiébaut, S. De Wit, O. Kirk, E. Fontas and 3 more. New England Journal of Medicine, 2007

1,446 citations recorded by the source corpus.

Subfields: Emergency Medicine, Infectious Diseases, Surgery

View Paper: https://www.semanticscholar.org/paper/0ae41cc83f6a151d3910221b1b27635f79179e7f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Worm
2. N. Friis‐Møller
3. W. El-Sadr
4. F. Dabis
5. A. Monforte
6. S. De Wit
7. M. Law
8. O. Kirk

Citations in the corpus

• Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. (2010, background): “Of interest, the associations reported for the 2 PIs (12% per year for indinavir and 13% per year for lopinavir-ritonavir) are both slightly lower than that previously reported from the D: A:D study for the PI drug class as a whole (16% per additional year) [5].”